Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COATS genotype-guided P2Y12 selection study in oral anticoagulated PCI patients
NL-OMON58922Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor and clopidogrel in coronary arteriosclerosis (4 arms), sponsored by Erasmus MC. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
ticagrelorclopidogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON58922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58922.